Publication Type : Journal Article
Thematic Areas : Biotech
Publisher : Molecular Pharmacology
Source : Molecular Pharmacology, Volume 82, Issue 4, p.614-622 (2012)
Url : https://pubmed.ncbi.nlm.nih.gov/22745359/
Campus : Amritapuri, Coimbatore
School : School of Biotechnology, School of Physical Sciences
Center : Biotechnology, Phytochemistry Labs
Department : biotechnology, Department of Sciences
Year : 2012
Abstract : Cashew nut shell liquid (CNSL) has been used in traditional medicine for the treatment of a wide variety of pathophysiological conditions. To further define the mechanism of CNSL action, we investigated the effect of cashew nut shell extract (CNSE) on two matrix metalloproteinases, MMP-2/gelatinase A and MMP-9/gelatinase B, which are known to have critical roles in several disease states. We observed that the major constituent of CNSE, anacardic acid, markedly inhibited the gelatinase activity of 3T3-L1 cells. Our gelatin zymography studies on these two secreted gelatinases, present in the conditioned media from 3T3-L1 cells, established that anacardic acid directly inhibited the catalytic activities of both MMP-2 and MMP-9. Our docking studies suggested that anacardic acid binds into the MMP-2/9 active site, with the carboxylate group of anacardic acid chelating the catalytic zinc ion and forming a hydrogen bond to a key catalytic glutamate side chain and the C15 aliphatic group being accommodated within the relatively large S1′ pocket of these gelatinases. In agreement with the docking results, our fluorescence-based studies on the recombinant MMP-2 catalytic core domain demonstrated that anacardic acid directly inhibits substrate peptide cleavage in a dose-dependent manner, with an IC50nbsp;of 11.11 μM. In addition, our gelatinase zymography and fluorescence data confirmed that the cardol-cardanol mixture, salicylic acid, and aspirin, all of which lack key functional groups present in anacardic acid, are much weaker MMP-2/MMP-9 inhibitors. Our results provide the first evidence for inhibition of gelatinase catalytic activity by anacardic acid, providing a novel template for drug discovery and a molecular mechanism potentially involved in CNSL therapeutic action.
Cite this Research Publication : A. Omanakuttan, Dr. Jyotsna Nambiar, Rodney M. Harris, Chinchu Bose, Pandurangan Nanjan, Rebu K. Varghese, Geetha B. Kumar, John A. Tainer, Dr. Asoke Banerji, J. Jefferson P. Perry, and Dr. Bipin G. Nair, “Anacardic Acid Inhibits the Catalytic Activity of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9”, Molecular Pharmacology, vol. 82, no. 4, pp. 614-622, 2012